Purpose This phase II study evaluated efficacy of single-agent erlotinib for chemotherapy-
naïve patients with advanced/metastatic NSCLC who were ineligible for platinum doublets …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Background The clinical benefit of erlotinib in treating epidermal growth factor receptor
(EGFR) wildtype non-small cell lung cancer (NSCLC) has been questioned. We examined …

In patients with advanced non-small cell lung cancer (NSCLC), the benefit-to-risk ratio of
doublet-targeted agents versus single agent is not clear. A systematic review and …

Background: This phase II study evaluated efficacy of first-line erlotinib therapy for chemo-
naïve patients with non-small cell lung cancer (NSCLC) by their clinicopathological and/or …

7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …

7160 Background: The HER1/EGFR inhibitor erlotinib significantly prolongs survival of
patients with previously-treated advanced NSCLC. Methods for selecting patients most likely …

8006 Background: E and D are standard cares for previously treated patients with advanced
NSCLC. Although E shows significant clinical benefits over best supportive care in the EGFR …

Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …